PT - JOURNAL ARTICLE AU - Bignardi, Paulo R AU - de Andrade Castello, Paula AU - de Matos Aquino, Bruno AU - Alvares Delfino, Vinicius Daher TI - Is the vitamin D status of patients with COVID-19 associated with reduced mortality? AID - 10.1101/2021.03.25.21254310 DP - 2021 Jan 01 TA - medRxiv PG - 2021.03.25.21254310 4099 - http://medrxiv.org/content/early/2021/03/26/2021.03.25.21254310.short 4100 - http://medrxiv.org/content/early/2021/03/26/2021.03.25.21254310.full AB - Objective A systematic review with meta-analysis was performed to assess a possible association between plasma vitamin D levels and mortality in patients with COVID – 19.Methods PubMed, EMBASE, and Cochrane Library databases were searched. Studies involving COVID-19 patients that reported an association between plasma vitamin D levels and COVID-19 mortality published until February 5, 2020, were included. The risk ratio (RR) and confidence interval (CI) were pooled using a fixed-effects or random-effects model.Results A total of 11 studies that measured plasma vitamin D levels at admission were included in the meta-analysis, ten cohorts and one case-controls. Low plasma vitamin D levels (25(OH)D) in patients with COVID-19 were not associated with mortality (RR=1.35, 95%CI 0.84–1.86). Subgroup analysis by vitamin D cut-off (<20 or 25 ng/ml and <10 or 12 ng/ml) showed were not associated with mortality. When the RR in mortality analysis was calculated included four studies that did not perform adjusted analysis for confounding factors, the result was 1.43 (95% CI 1.18-1.69), suggesting that confounders may have led many observational studies to incorrectly estimate the association between vitamin D status and mortality in COVID-19 patients.Conclusion Deficient vitamin D levels were not associated with a higher mortality rate in patients with COVID-19. Randomized clinical trials are needed to assess this association.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No applicableAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNot applicable